Newsroom
Spotlight Story
Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions
Read more
Press Releases
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES)…
Read More
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual…
Read More
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F…
Read More
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver…
Read More
UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia…
Read More
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (…
Read MoreUCB Stories
Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions
Read More
Closing gaps in HS care through community engagement and scientific innovation
Read More
A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology
Read More
Powering the dreams of people impacted by myasthenia gravis (MG)
Read More
Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community
Read More
